Again, are you just showing your own capacity of realizing value, midswe?
They are selling a possible annual sales of 4-500 MUSD on each of the US and EU market.
Have you noticed that Epicept will take Myrx to the court, look at the Q-report. Myrx will have to decide themselfs if it is worth the fight or if they should join Epicept/Amiket when the possibillity to beat them seem not to good. An understatement?
MYRX have appr 90 MUSD in cash. Open for a transition.